



Press Release

Göteborg, Sweden

Helsingfors, Finland

May 8, 2001

A⁺ SCIENCE INVEST AB AND CARBION OY SIGN LICENCE AGREEMENT REGARDING HELICOBACTER PYLORI

A⁺ Science Invest AB has entered into an exclusive licence agreement with Carbion OY regarding the development of novel treatments for Helicobacter pylori infections based upon an A⁺ patent. The licence agreement will generate milestone and royalty payments to A⁺.

Helicobacter pylori infection is one of the most common infectious diseases in the world. It is estimated that between 5% and 10% of the world's population suffer from gastric ulcer at least once during their lifetime. The gastric ulcer is caused, in most cases, by Helicobacter pylori bacteria, which is also a risk factor for gastric cancer.

The main objective with the invention is to provide new ways to treat conditions caused by H. pylori by finding specific receptors in the human gastric epithelium.

The goal of this agreement is to develop and commercialise efficacious carbohydrate-based pharmaceuticals against H. pylori infections.

The research activities are conducted in collaboration with Professor Karl-Anders Karlsson, Institute of Medical Biochemistry, Göteborg University.

"Treatment of diseases in the gastro intestinal tract is a prioritised area within A⁺. We have been cooperating with researchers at several Swedish universities since our establishment in 1997. Now, we are looking forward to collaborating with Carbion OY and its group of leading Finnish glycobiologists", says Boo Edgar, Managing Director at A⁺.

For further information, please contact Erik Ahlberg, Market & Business Development Director, phone: + 46 31 7782137, +46 708 888429, or Boo Edgar, Managing Director, phone: +46 31 7782131, +46 708 888427.

A⁺ Science Invest AB (publ.) - www.a-plusscience.com - founded in 1997, is a bioscience company, identifying, evaluating, acquiring, developing, financing and commercialising patentable, patented and marketable inventions in the life science field. The project portfolio comprises some 30 projects in medicine and biotechnology. Major shareholders are the National Pension Insurance Fund, Sixth Fund Board, The Holding Company at Göteborg University, Investor Investments Novare Limited, Biofund and Optiomis OY.

Carbion OY - www.carbion.net - is a company incorporated in late 1999 by a group of leading Finnish glycobiologists to commercialise their inventions in carbohydrate synthesis and analysis. The ultimate goal is to develop novel carbohydrate-based pharmaceuticals.